PDXK and non-small cell lung carcinoma: On the other hand, it has been demonstrated that PDXK knockdown in human NSCLC cells protects against the cytotoxic activity of different agents, in particular the chemotherapy agent cisplatin, whereas PN administration improved, in a manner that depends on the presence of PDXK, cisplatin anti-tumour effect by exacerbating DNA damage.